Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | CTSE | P14091 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14829776 | 0.87 | KDM4E (0.40) | KDM4EMAPTTHRBHTT | |
| SCHEMBL15878935 | 0.85 | MAPT (0.49) | KDM4EMAPTTHRBHTTMEN1 | |
| SCHEMBL1501612 | 0.79 | GPR119 (0.52) | KDM4EMAPTTHRBHTTMEN1 | |
| SCHEMBL23635373 | 0.77 | MAPT (0.49) | KDM4EMAPTTHRBHTTMEN1 | |
| SCHEMBL30926528 | 0.77 | KDM4E (0.46) | KDM4EMAPTTHRBHTTGPR119 | |
| SCHEMBL15878611 | 0.76 | KDM4E (0.54) | KDM4EMAPTTHRBHTTMEN1 | |
| SCHEMBL23459591 | 0.76 | GPR119 (0.57) | KDM4EMAPTTHRBMEN1KMT2A | |
| SCHEMBL4695031 | 0.76 | THRB (0.51) | KDM4EMAPTTHRBHTTMEN1 | |
| SCHEMBL5636028 | 0.76 | THRB (0.51) | KDM4EMAPTTHRBHTTGPR119 | |
| SCHEMBL15033048 | 0.76 | HTT (0.63) | KDM4EMAPTTHRBHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013049591-A2 | DUAL INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | VERSEON CORPORATION (US) | 2013-04-04 | — | — | WO | claimed |
| US-20250236622-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF WRN | INCYTE CORPORATION (US) | 2025-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236622-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF WRN | WRN, BLM, RECQL | KDM4E 3651/4885MAPT 4634/4885THRB 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.